Jeremy Barry

Jeremy Barry is a Senior Scientist at Alnylam Pharmaceuticals since August 2022, having previously served as a Scientific Investigator at GSK from April 2014 to August 2022. At GSK, Jeremy Barry collaborated on preclinical studies related to drug tissue distribution and integrated quantitative imaging mass spectrometry data with other methodologies. Prior experience includes research assistant positions at North Carolina State University, where Jeremy focused on mass spectrometry techniques, and at UNC Greensboro, working on the separation of Alzheimer's disease biomarkers. Jeremy Barry holds a Ph.D. in Analytical Chemistry from North Carolina State University, a Master’s in Analytical Chemistry from the University of North Carolina at Greensboro, and dual Bachelor’s degrees in Chemistry and Forensic Science from the University of New Haven.